SCM
IKT icon

Sterling Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Sterling Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.97K Sell
2,447
-832
-25% -$1.49K ﹤0.01% 2615
2026
Q1 		$5.51K Buy
3,279
+59
+2% +$105 ﹤0.01% 2680
2025
Q4 		$6.6K Sell
3,220
-607
-16% -$966 ﹤0.01% 2795
2025
Q3 		$6.2K Buy
3,827
+2,322
+154% +$4.02K ﹤0.01% 2699
2025
Q2 		$2.94K Buy
+1,505
New +$2.95K ﹤0.01% 2794

Other funds holding IKT

AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
TCA
Transcend Capital Advisors Madison, New Jersey $1.48B AUM 25.55% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Sterling Capital Management's IKT Position: Q2 2026 in Review

Sterling Capital Management reduced its Inhibikase Therapeutics (IKT) stake by 25% in Q2 2026, selling an estimated $1.49K and leaving 2,447 shares worth $4.97K. The position accounts for ﹤0.01% of the portfolio, ranked #2615.

Sterling Capital Management first reported a position in IKT in Q2 2025 and has held it in 5 quarters since. The position peaked at $6.6K in Q4 2025. 13 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Sterling Capital Management held 2,447 shares of Inhibikase Therapeutics worth $4.97K as of Q2 2026.
  • Sterling Capital Management sold 832 Inhibikase Therapeutics shares in Q2 2026, an estimated $1.49K.
  • Inhibikase Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2615 holding.
  • Sterling Capital Management first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Sterling Capital Management's Inhibikase Therapeutics position peaked at $6.6K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.